Immuneering (NASDAQ:IMRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Immuneering (NASDAQ:IMRX) had its price objective lifted by research analysts at Needham & Company LLC from $11.00 to $18.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 303.59% from the stock’s current price.

Several other brokerages also recently weighed in on IMRX. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Immuneering in a report on Tuesday, May 19th. Cantor Fitzgerald assumed coverage on shares of Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target for the company. Finally, Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immuneering currently has an average rating of “Moderate Buy” and an average target price of $17.57.

Immuneering Stock Performance

Immuneering stock opened at $4.46 on Monday. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08. The company has a market capitalization of $288.56 million, a price-to-earnings ratio of -3.81 and a beta of 0.41. The stock has a fifty day moving average of $4.80 and a two-hundred day moving average of $5.09.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. On average, analysts forecast that Immuneering will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empery Asset Management LP purchased a new stake in shares of Immuneering during the 4th quarter worth about $17,601,000. Vanguard Group Inc. increased its position in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares in the last quarter. State Street Corp raised its holdings in Immuneering by 1,289.7% in the fourth quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after buying an additional 2,229,374 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Immuneering by 10.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock valued at $13,121,000 after buying an additional 195,176 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Immuneering during the third quarter valued at approximately $6,602,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.